Bicycle Therapeutics (BCYC) News Today $14.68 -0.32 (-2.13%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period JMP Securities Cuts Bicycle Therapeutics (NASDAQ:BCYC) Price Target to $26.00December 21 at 2:53 AM | americanbankingnews.comHC Wainwright Has Positive Forecast for BCYC Q1 EarningsDecember 21 at 1:59 AM | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Shares Down 2.9% on Analyst DowngradeDecember 21 at 1:18 AM | americanbankingnews.comBicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strengthDecember 20 at 11:18 PM | investing.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up Following Insider Buying ActivityDecember 20 at 1:07 AM | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.9% Following Analyst DowngradeBicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.9% After Analyst DowngradeDecember 19 at 10:08 AM | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for BCYCBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Bicycle Therapeutics in a report issued on Monday, December 16th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.December 19 at 5:55 AM | marketbeat.comBicycle Therapeutics price target lowered to $26 from $32 at JMP SecuritiesDecember 18 at 7:33 PM | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up on Insider Buying ActivityBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up on Insider Buying ActivityDecember 18 at 10:28 AM | marketbeat.comJMP Securities Has Lowered Expectations for Bicycle Therapeutics (NASDAQ:BCYC) Stock PriceJMP Securities decreased their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a report on Wednesday.December 18 at 9:56 AM | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $7,670,000.00 in StockDecember 18 at 5:24 AM | insidertrades.comHC Wainwright Issues Pessimistic Forecast for Bicycle Therapeutics (NASDAQ:BCYC) Stock PriceDecember 18 at 1:55 AM | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $7,670,000.00 in StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) Director Bros. Advisors Lp Baker acquired 500,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was purchased at an average price of $15.34 per share, for a total transaction of $7,670,000.00. Following the purchase, the director now owns 9,995,274 shares of the company's stock, valued at $153,327,503.16. The trade was a 5.27 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.December 17, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Director Acquires $13,559,062.72 in StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) Director Bros. Advisors Lp Baker purchased 985,397 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the transaction, the director now directly owns 9,537,643 shares of the company's stock, valued at $131,237,967.68. This represents a 11.52 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.December 17, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Sees Unusually-High Trading Volume - What's Next?Bicycle Therapeutics (NASDAQ:BCYC) Sees Strong Trading Volume - Should You Buy?December 17, 2024 | marketbeat.comBreaking Down Bicycle Therapeutics: 8 Analysts Share Their ViewsDecember 16, 2024 | benzinga.comBicycle Therapeutics (NASDAQ:BCYC) Shares Up 8.7% - Should You Buy?Bicycle Therapeutics (NASDAQ:BCYC) Trading 8.7% Higher - Here's WhyDecember 16, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Price Target Cut to $33.00 by Analysts at HC WainwrightHC Wainwright cut their target price on Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating for the company in a research note on Monday.December 16, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsDecember 16, 2024 | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of "Moderate Buy" by BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has received an average rating of "Moderate Buy" from the nine brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company.December 16, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Down After Analyst DowngradeDecember 15, 2024 | americanbankingnews.comB. Riley Lowers Bicycle Therapeutics (NASDAQ:BCYC) Price Target to $17.00December 15, 2024 | americanbankingnews.comBicycle Therapeutics plc (BCYC)December 14, 2024 | finance.yahoo.comFmr LLC Purchases New Shares in Bicycle Therapeutics plc (NASDAQ:BCYC)Fmr LLC purchased a new stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 150,516 shares of the company's stock, valued at approximately $3,406,000. Fmr LLC owned approximately 0.32%December 14, 2024 | marketbeat.comWe're Hopeful That Bicycle Therapeutics (NASDAQ:BCYC) Will Use Its Cash WiselyDecember 13, 2024 | finance.yahoo.comOptimistic Buy Rating on Bicycle Therapeutics Amidst Pipeline Promises and Differentiation ChallengesDecember 13, 2024 | markets.businessinsider.comB. Riley Issues Pessimistic Forecast for Bicycle Therapeutics (NASDAQ:BCYC) Stock PriceB. Riley cut their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday.December 13, 2024 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Down - What's Next?Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Down - Time to Sell?December 13, 2024 | marketbeat.comBicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene AmplificationDecember 12, 2024 | businesswire.comBicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsDecember 11, 2024 | finance.yahoo.comBicycle Therapeutics plc: Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology ExpertsDecember 10, 2024 | finanznachrichten.deThe Manufacturers Life Insurance Company Increases Stock Position in Bicycle Therapeutics plc (NASDAQ:BCYC)The Manufacturers Life Insurance Company grew its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 33.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 129,705 shares of the company's stock after acquiring an additional 32,313 shares dDecember 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Increases Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)Point72 Asset Management L.P. increased its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 1,438.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 899,799 shares of the company's stockDecember 7, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC reduced its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 16.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 445,396 shares of the compDecember 4, 2024 | marketbeat.comVerition Fund Management LLC Decreases Stake in Bicycle Therapeutics plc (NASDAQ:BCYC)Verition Fund Management LLC cut its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 20.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,151 shares of the company's stock aftDecember 3, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Sees Significant Growth in Short InterestBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,520,000 shares, an increase of 7.6% from the October 31st total of 3,270,000 shares. Based on an average trading volume of 452,200 shares, the short-interest ratio is presently 7.8 days.December 3, 2024 | marketbeat.comTybourne Capital Management HK Ltd. Has $31.56 Million Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)Tybourne Capital Management HK Ltd. lessened its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 7.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,394,535 shares of the company's stock after selling 115,November 28, 2024 | marketbeat.comPositive Outlook on Bicycle Therapeutics Driven by Promising Data and Upcoming UpdatesNovember 26, 2024 | markets.businessinsider.comBicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program UpdateNovember 25, 2024 | businesswire.comWestfield Capital Management Co. LP Increases Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Westfield Capital Management Co. LP raised its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 21.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,850,945 shares of the company's stock after purchNovember 25, 2024 | marketbeat.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $17.20 Million Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 14.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 759,887 shares of the company's stock after selNovember 24, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recoNovember 21, 2024 | marketbeat.comB. Riley Expects Weaker Earnings for Bicycle TherapeuticsBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - B. Riley lowered their FY2024 EPS estimates for Bicycle Therapeutics in a research report issued on Monday, November 18th. B. Riley analyst K. Patel now anticipates that the company will earn ($2.83) per share for the year, down from their prNovember 20, 2024 | marketbeat.comPrincipal Financial Group Inc. Takes $10.03 Million Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Principal Financial Group Inc. purchased a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 443,141 shareNovember 19, 2024 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Short Interest UpdateBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 3,270,000 shares, an increase of 12.0% from the October 15th total of 2,920,000 shares. Based on an average daily volume of 403,700 shares, the short-interest ratio is presently 8.1 days.November 16, 2024 | marketbeat.comBicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potentialNovember 15, 2024 | uk.investing.comBicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potentialNovember 15, 2024 | uk.investing.comWichita looking for public input on Draft Bicycle PlanNovember 14, 2024 | msn.comTravis Alvin Thompson Sells 6,256 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) StockNovember 14, 2024 | insidertrades.comIs Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025?November 14, 2024 | msn.com Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin BCYC Media Mentions By Week BCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCYC News Sentiment▼0.550.61▲Average Medical News Sentiment BCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCYC Articles This Week▼305▲BCYC Articles Average Week Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Apellis Pharmaceuticals News Today Scholar Rock News Today Biohaven News Today Avidity Biosciences News Today Immunovant News Today Organon & Co. News Today PTC Therapeutics News Today Verona Pharma News Today Rhythm Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCYC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts